- 16 Sep 2020 – Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
- 9 Sep 2020 – Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
- 4 Sep 2020 – Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
- 27 Aug 2020 – Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Alligator Bioscience Virtual R&D Day - Aug 27
Alligator held a virtual R&D Day on August 27, in which CEO Per Norlén and COO Malin Carlsson gave an update on the status and latest development steps in the company's clinical pipeline. Guest speaker, Professor Ignacio Melero at University of Navarra, gave his view on 4-1BB, the target for ATOR-1017. Listen to the presentations here.